These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38530862)

  • 1. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals.
    Cossu MV; Cattaneo D; Moschese D; Giacomelli A; Soloperto S; D'Avolio A; Antinori S; Gori A; Rizzardini G; Gervasoni C
    J Antimicrob Chemother; 2024 May; 79(5):1126-1132. PubMed ID: 38530862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine.
    Rubenstein E; Diemer M; Goldwirt L; Lascoux-Combe C; Chaix ML; Rami A; Ponscarme D; Lafaurie M; Denis B; De Castro N; Gras J; Liegeon G; Sellier PO; Deville L; Chevret S; Delaugerre C; Molina JM
    AIDS; 2024 Jul; 38(8):1267-1269. PubMed ID: 38814715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV.
    Cossu MV; D'Avolio A; Gervasoni C; Giacomelli A; Cattaneo D; Moschese D
    Antimicrob Agents Chemother; 2024 May; 68(5):e0017524. PubMed ID: 38534104
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
    Overton ET; Richmond G; Rizzardini G; Jaeger H; Orrell C; Nagimova F; Bredeek F; García Deltoro M; Swindells S; Andrade-Villanueva JF; Wong A; Khuong-Josses MA; Van Solingen-Ristea R; van Eygen V; Crauwels H; Ford S; Talarico C; Benn P; Wang Y; Hudson KJ; Chounta V; Cutrell A; Patel P; Shaefer M; Margolis DA; Smith KY; Vanveggel S; Spreen W
    Lancet; 2021 Dec; 396(10267):1994-2005. PubMed ID: 33308425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
    Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
    Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.
    Fisk-Hoffman RJ; Ranger SS; Gracy A; Gracy H; Manavalan P; Widmeyer M; Leeman RF; Cook RL; Canidate S
    AIDS Patient Care STDS; 2024 Jun; 38(6):275-285. PubMed ID: 38686517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
    Gaur AH; Capparelli EV; Calabrese K; Baltrusaitis K; Marzinke MA; McCoig C; Van Solingen-Ristea RM; Mathiba SR; Adeyeye A; Moye JH; Heckman B; Lowenthal ED; Ward S; Milligan R; Samson P; Best BM; Harrington CM; Ford SL; Huang J; Crauwels H; Vandermeulen K; Agwu AL; Smith-Anderson C; Camacho-Gonzalez A; Ounchanum P; Kneebone JL; Townley E; Bolton Moore C; ;
    Lancet HIV; 2024 Apr; 11(4):e211-e221. PubMed ID: 38538160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.
    van Welzen BJ; Van Lelyveld SFL; Ter Beest G; Gisolf JH; Geerlings SE; Prins JM; Van Twillert G; Van Nieuwkoop C; Van der Valk M; Burger D; Wensing AMJ
    Clin Infect Dis; 2024 Jul; 79(1):189-195. PubMed ID: 38207125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
    Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
    Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reply to Cossu et al., "Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV".
    Han K
    Antimicrob Agents Chemother; 2024 May; 68(5):e0020424. PubMed ID: 38534102
    [No Abstract]   [Full Text] [Related]  

  • 12. A HIV Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine.
    Valin N; Lambert-Niclot S; Torres E; Meynard JL; Périllaud-Dubois C; Morand-Joubert L; Lacombe K
    Clin Infect Dis; 2024 Jul; 79(1):196-197. PubMed ID: 38513236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
    Jaeger H; Overton ET; Richmond G; Rizzardini G; Andrade-Villanueva JF; Mngqibisa R; Hermida AO; Thalme A; Belonosova E; Ajana F; Benn PD; Wang Y; Hudson KJ; Español CM; Ford SL; Crauwels H; Margolis DA; Talarico CL; Smith KY; van Eygen V; Van Solingen-Ristea R; Vanveggel S; Spreen WR
    Lancet HIV; 2021 Nov; 8(11):e679-e689. PubMed ID: 34648734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
    Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.
    Rajoli RKR; Back DJ; Rannard S; Meyers CF; Flexner C; Owen A; Siccardi M
    Clin Pharmacokinet; 2018 Feb; 57(2):255-266. PubMed ID: 28540638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
    Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ;
    Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.
    Thoueille P; Saldanha SA; Schaller F; Choong E; Munting A; Cavassini M; Braun D; Günthard HF; Kusejko K; Surial B; Furrer H; Rauch A; Rougemont M; Ustero P; Calmy A; Stöckle M; Marzolini C; Di Benedetto C; Bernasconi E; Schmid P; Piso RJ; Andre P; Girardin FR; Guidi M; Buclin T; Decosterd LA;
    Lancet Reg Health Eur; 2024 Jan; 36():100793. PubMed ID: 38162253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Off-label Use of Long-Acting Injectable Antiretroviral Therapy: A Single Center Retrospective Review of Youth Living With HIV With Detectable HIV RNA Starting Injectable Therapy.
    Rousseau A; McGrath E; Benjamins L; Cockern S; Meade J; Houston K; Breaux M; Secord E
    J Pediatric Infect Dis Soc; 2024 May; 13(5):285-287. PubMed ID: 38591356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
    Orkin C; Bernal Morell E; Tan DHS; Katner H; Stellbrink HJ; Belonosova E; DeMoor R; Griffith S; Thiagarajah S; Van Solingen-Ristea R; Ford SL; Crauwels H; Patel P; Cutrell A; Smith KY; Vandermeulen K; Birmingham E; St Clair M; Spreen WR; D'Amico R
    Lancet HIV; 2021 Nov; 8(11):e668-e678. PubMed ID: 34656207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.
    Wohlfeiler MB; Brunet L; Cochran Q; Fusco JS; Hsu RK; Fusco GP
    J Int Assoc Provid AIDS Care; 2024; 23():23259582241245223. PubMed ID: 38613372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.